Wang, Weimin
Green, Michael
Choi, Jae Eun
Gijón, Miguel
Kennedy, Paul D.
Johnson, Jeffrey K.
Liao, Peng
Lang, Xueting
Kryczek, Ilona
Sell, Amanda
Xia, Houjun
Zhou, Jiajia
Li, Gaopeng
Li, Jing
Li, Wei
Wei, Shuang
Vatan, Linda
Zhang, Hongjuan
Szeliga, Wojciech
Gu, Wei
Liu, Rebecca
Lawrence, Theodore S.
Lamb, Candice
Tanno, Yuri
Cieslik, Marcin
Stone, Everett
Georgiou, George
Chan, Timothy A.
Chinnaiyan, Arul
Zou, Weiping
Article History
Received: 24 April 2018
Accepted: 26 March 2019
First Online: 1 May 2019
Competing interests
: G.G. and E.S. are inventors on intellectual property related to cyst(e)inase and hold equity interest in Aeglea Biotherapeutics Inc. T.A.C. is a co-founder of and holds equity in Gritstone Oncology. T.A.C. holds equity in An2H. T.A.C. acknowledges grant funding from Bristol-Myers Squibb, AstraZeneca, Illumina, Pfizer, An2H, and Eisai. T.A.C. has served as a paid advisor for Bristol-Myers Squibb, Illumina, Eisai, and An2H. Memorial Sloan Kettering has licensed the use of tumour mutation burden (TMB) for the identification of patients that will benefit from immune checkpoint therapy to PGDx. Memorial Sloan Kettering and T.A.C. receive royalties as part of this licensing agreement. W.Z. has served as a consultant or advisor for Lycera, NGM, Synlogic, and Henlix.